Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Non Operating Income (2016 - 2025)

Altimmune (ALT) has disclosed Non Operating Income for 16 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income rose 10150.0% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$295000.0, a 106.49% decrease, with the full-year FY2024 number at $48000.0, down 71.08% from a year prior.
  • Non Operating Income was $1.8 million for Q3 2025 at Altimmune, down from $2.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.4 million in Q1 2024 to a low of -$4.5 million in Q4 2024.
  • A 5-year average of $568947.4 and a median of $117000.0 in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 22475.0% in 2024, then skyrocketed 10150.0% in 2025.
  • Altimmune's Non Operating Income stood at $117000.0 in 2021, then soared by 1125.64% to $1.4 million in 2022, then plummeted by 98.61% to $20000.0 in 2023, then plummeted by 22475.0% to -$4.5 million in 2024, then skyrocketed by 141.23% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Non Operating Income are $1.8 million (Q3 2025), $2.3 million (Q2 2025), and $15000.0 (Q1 2025).